Head-To-Head Review: Aptose Biosciences (APTO) & Regulus Therapeutics (RGLS)
Aptose Biosciences (NASDAQ: APTO) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Volatility and Risk
Aptose Biosciences has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.
This is a breakdown of recent recommendations for Aptose Biosciences and Regulus Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aptose Biosciences currently has a consensus target price of $7.00, indicating a potential upside of 389.51%. Regulus Therapeutics has a consensus target price of $4.10, indicating a potential upside of 250.43%. Given Aptose Biosciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe Aptose Biosciences is more favorable than Regulus Therapeutics.
This table compares Aptose Biosciences and Regulus Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
4.6% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 22.0% of Regulus Therapeutics shares are owned by institutional investors. 4.8% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Aptose Biosciences and Regulus Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Aptose Biosciences||N/A||N/A||-$12.87 million||($0.73)||-1.96|
|Regulus Therapeutics||$257,999.00||470.65||-$73.96 million||($1.54)||-0.76|
Aptose Biosciences has higher revenue, but lower earnings than Regulus Therapeutics. Aptose Biosciences is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aptose Biosciences beats Regulus Therapeutics on 8 of the 12 factors compared between the two stocks.
About Aptose Biosciences
Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company’s APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.
About Regulus Therapeutics
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.